Net sales reaching over 100 msek and the EBITDA of 24.5 msek is the highest in the company's history
SIGNIFICANT EVENTS DURING THE SECOND QUARTER 2024 (APR - JUN)
- Larger repeat industry order to significant client of 2.2 MUSD was announced in May.
- CEO Göran Malmberg decided to step down from his position at the end of the year. The recruitment of a successor has been initiated. The plan for Malmberg is to step into an advisor role coming into 2025.
SECOND QUARTER 2024 (APR - JUN)
- Order intake amounted to 71 (77) MSEK, a decrease of -8%.
- Net sales amounted to 101 (74) MSEK, an increase of 36%, whereof 34% organic, 1% acquired and 1% currency effect.
- Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 24.5 (10.7) MSEK.
- Net income for the period amounted to 17.2 (1.5) MSEK.
- Earnings per share (EPS) were 0.67 (0.06) SEK.
- Cash flow from operating activities amounted to 5.3 (5.2) MSEK.
SIX MONTHS 2024 (JAN - JUN)
- Order intake amounted to 109 (135) MSEK, a decrease of -19%.
- The order book by the end of the period was 114 (125) MSEK, a decrease of -9%.
- Net sales amounted to 146 (139) MSEK, an increase of 5%, whereof 4% organic, 1% acquired and 0% currency effect.
- Earnings before interest, tax, depreciation, and amortization (EBITDA) amounted to 6.1 (17.9) MSEK.
- Net income for the period amounted to -7.4 (0.0) MSEK.
- Earnings per share (EPS) were -0.29 (0.0) SEK.
- Cash flow from operating activities amounted to 7.2 (2.5) MSEK.
Webcast presentation of the interim report
Date: July 23, 2024
Time: 10:00 CEST
To join the presentation, please visit https://investor.mentice.com/
For more information, please contact:
Göran Malmberg, CEO, Mentice
E-post: goran.malmberg@mentice.com
US Mobile. +1 (312) 860 5610
Sweden Mobile +46 (0) 703 09 22 22
About Mentice
Mentice (STO: MNTC) is the world leader in proficiency based simulation solutions for image guided interventional therapies. Our solutions help healthcare professionals acquire, retain, and enhance their procedural skills driving improved productivity and outcomes. Mentice solutions are scientifically validated and have been specifically developed for healthcare providers and the medical device industry. Neurovascular, cardiovascular, and peripheral interventions are just some of the clinical areas covered by our solutions. Learn more about the features and benefits of Mentice solutions at: www.mentice.com
Marketplace| Nasdaq First North Growth Market, Stockholm | Ticker symbol MNTC
Certified Adviser| FNCA Sweden AB
This information is information that Mentice is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-23 08:30 CEST.
